ErreDue 1H2026 net profit more than doubles to €2.43 million; revenue jumps 97% to €14.21 million
Bitget2026/09/29 17:11- ErreDue posted 1H2026 revenue of €14.2 million, up 97% year-on-year.
- Net income rose to €2.4 million, while EBITDA climbed to €4.1 million; EBITDA margin widened 3.9 percentage points to 28.9%.
- Net financial debt stood at net cash of €10.85 million at June 30, down from €14.67 million at Dec. 31, 2025.
- Backlog totaled about €27 million at June 30, split roughly evenly between second-half 2026 and 2027 deliveries.
- CEO Francesca Barontini cited five megawatt-scale hydrogen plant deliveries, while noting capacity constraints ahead of the new Livorno site completion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ido Ben-Natan: Frequent on-chain security incidents, AI agents will increase risks
BTC rebounds and breaks through 83,000 USDT, with a 24-hour decrease of 1%
Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly
The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.
Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results
Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.
Crypto prices
More
